Literature DB >> 16187235

Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast?

Shailesh Chaturvedi1, Catherine McLaren, Andrew C Schofield, Keith N Ogston, Tarun K Sarkar, Andrew W Hutcheon, Iain D Miller, Steven D Heys.   

Abstract

This study aimed to evaluate patterns of local and distant disease recurrence in patients having primary chemotherapy and compared patterns of relapse in patients with a complete pathological response with those who had residual breast disease. This is an observational study using a sequential series of patients treated with primary chemotherapy. They were followed up for a minimum of 5 years. All data was collected prospectively. Three hundred forty-one consecutive patients with breast cancer were treated with up to eight cycles of doxorubicin-based chemotherapy. Clinical and pathological response rates were evaluated and patients were followed up for disease recurrence (local and distant) and overall survival. Fifty-two patients (16.5%) had a complete pathological response to chemotherapy. Distant disease recurrence occurred in nine patients (17.3%) but no local recurrence was observed. In patients not having a complete pathological response, 86 patients (32.6%) subsequently developed metastases. Local recurrence of disease occurred in 12 (4.5%). There was a statistically significant difference in overall survival between patients whose tumours had a complete pathological response compared with patients who had residual disease in the breast following chemotherapy (88% versus 70% at 5 years, p = 0.036). Following primary chemotherapy, about 84% of patients had residual disease in the breast. Surgery is necessary to ensure complete removal of residual tumour and excellent rates of local control are achievable. A complete pathological response is associated with fewer local and distant recurrences as well as improved survival although there are no differences in time to development of metastatic relapse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187235     DOI: 10.1007/s10549-005-4615-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Inflammatory breast cancer after neoadjuvant chemotherapy: can magnetic resonance imaging precisely diagnose the final pathological response?

Authors:  J-H Chen; R S Mehta; O Nalcioglu; M-Y Su
Journal:  Ann Surg Oncol       Date:  2008-09-19       Impact factor: 5.344

2.  Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.

Authors:  Zsolt Horváth; László Torday; Erika Hitre; Erna Ganofszky; Eva Juhos; Ferenc Czeglédi; László Urbán; Csaba Polgár; István Láng; Sándor Eckhardt; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2010-12-14       Impact factor: 3.201

3.  Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.

Authors:  Yukie Enomoto; Takashi Morimoto; Arisa Nishimukai; Tomoko Higuchi; Ayako Yanai; Yoshimasa Miyagawa; Keiko Murase; Michiko Imamura; Yuichi Takatsuka; Takashi Nomura; Masashi Takeda; Takahiro Watanabe; Seiichi Hirota; Yasuo Miyoshi
Journal:  Int J Clin Oncol       Date:  2015-09-04       Impact factor: 3.402

4.  Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers.

Authors:  Nilgun Yildirim; Melih Simsek; Mehmet Naci Aldemir; Mehmet Bilici; Salim Basol Tekin
Journal:  Eurasian J Med       Date:  2019-06

5.  Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype.

Authors:  Eun Sook Ko; Heon Han; Boo-Kyung Han; Sun Mi Kim; Rock Bum Kim; Gyeong-Won Lee; Yeon Hee Park; Seok Jin Nam
Journal:  Korean J Radiol       Date:  2015-08-21       Impact factor: 3.500

6.  Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapy.

Authors:  Toshiyuki Ishiba; Tsuyoshi Nakagawa; Takanobu Sato; Makoto Nagahara; Goshi Oda; Hitoshi Sugimoto; Mai Kasahara; Tokuko Hosoya; Kazunori Kubota; Tomoyuki Fujioka; Peter Danenberg; Kathleen Danenberg; Hiroyuki Uetake
Journal:  Springerplus       Date:  2015-12-24

7.  Prediction of neoadjuvant chemotherapy response using diffuse optical spectroscopy in breast cancer.

Authors:  Ying-Hua Yu; Xiao Zhu; Qin-Guo Mo; Ying Cui
Journal:  Clin Transl Oncol       Date:  2017-09-18       Impact factor: 3.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.